ZIPRASIDONE-WT
Main information
- Trade name:
- ZIPRASIDONE-WT ziprasidone (as hydrochloride) 80 mg capsule blister pack
- Active ingredient:
- Ziprasidone hydrochloride
- Available from:
- Medis Pharma Pty Ltd
- INN (International Name):
- Ziprasidone hydrochloride
- Medicine domain:
- Humans
- Medicine type:
- Allopathic drug
Documents
- for the general public:
- Public Assessment Report
-
- for the general public:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- for healthcare professionals:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for healthcare professionals.
Localization
- Available in:
-
Australia
- Language:
- English
Other information
Status
- Source:
- Dept. of Health,Therapeutic Goods Administration - Australia
- Authorization number:
- 221097
- Last update:
- 08-10-2017
Public Assessment Report
Public Summary
Summary for ARTG Entry:
221097
ZIPRASIDONE-WT ziprasidone (as hydrochloride) 80 mg capsule blister pack
ARTG entry for
Medicine Registered
Sponsor
Medis Pharma Pty Ltd
Postal Address
PO Box 6127,North Sydney, NSW, 2059
Australia
ARTG Start Date
5/03/2015
Product category
Medicine
Status
Active
Approval area
Drug Safety Evaluation Branch
Conditions
Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods
Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.
Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered
or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.
Products
1. ZIPRASIDONE-WT ziprasidone (as hydrochloride) 80 mg capsule blister pack
Product Type
Single Medicine Product
Effective date
23/05/2017
Warnings
See Product Information and Consumer Medicine Information for this product
Standard Indications
Specific Indications
for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy;,as
monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar I disorder.
Additional Product information
Container information
Type
Material
Life Time
Temperature
Closure
Conditions
Blister Pack
PA/Al/PVC/Al -
polyamide-aluminium
foil-polyvinylchloride/al
uminium foil
36 Months
Store below 30
degrees Celsius
Child resistant closure
Not recorded
Pack Size/Poison information
Pack Size
Poison Schedule
(S4) Prescription Only Medicine
Components
1. ZIPRASIDONE-WT ziprasidone (as hydrochloride) 80 mg capsule blister pack
Dosage Form
Capsule, hard
Route of Administration
Oral
Visual Identification
size 2 capsule: white body, blue cap
Active Ingredients
Ziprasidone hydrochloride
86.88 mg
© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior
written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.
Public Summary
Page 1 of
Produced at 26.11.2017 at 01:30:20 AEDT
This is not an ARTG Certificate document.
The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.
Visit www.tga.gov.au for contact information
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
Documents in other languages are available here
- Access to this document is only available to registered users.
Register now for full access
13-2-2019
Jurnista (hydromorphone hydrochloride) prolonged-release
Product defect correction - potentially damaged tablets
Therapeutic Goods Administration - Australia
1-2-2019
Safety of concentrated l‐lysine (base), l‐lysine monohydrochloride and l‐lysine sulfate produced using different strains of Corynebacterium glutamicum for all animal species based on a dossier submitted by FEFANA asbl
Published on: Thu, 31 Jan 2019 The EFSA FEEDAP Panel previously (2016) could not conclude on the safety of certain concentrated liquid l‐lysine (base), l‐lysine monohydrochloride (HCl) and l‐lysine sulfate products manufactured using different strains of Corynebacterium glutamicum. New information on the safety of these products was provided by the applicant. The recipient strain C. glutamicum KCTC 12307BP qualifies for qualified presumption of safety (QPS) approach for safety assessment, the genetic mo...
Europe - EFSA - European Food Safety Authority EFSA Journal
1-2-2019
Safety and efficacy of l‐lysine monohydrochloride and concentrated liquid l‐lysine (base) produced by fermentation using Corynebacterium glutamicum strain NRRL B‐50775 for all animal species based on a dossier submitted by ADM
Published on: Thu, 31 Jan 2019 The European Commission asked EFSA for an opinion on the safety for the target animals, consumer, user and the environment and on the efficacy of a l‐lysine monohydrochloride (HCl, minimum 98.5%) and of a concentrated liquid l‐lysine (base, minimum 50%) produced by a genetically modified strain of Corynebacterium glutamicum(NRRL B‐50775). They are intended to be used in feed or water for drinking for all animal species and categories. Neither the production strain C. gluta...
Europe - EFSA - European Food Safety Authority EFSA Journal
28-11-2018
Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)
Update - medicine shortage
Therapeutic Goods Administration - Australia
24-8-2018
Human medicines European public assessment report (EPAR): Gliolan, 5-aminolevulinic acid hydrochloride, Revision: 4, Authorised
Europe - EMA - European Medicines Agency
21-8-2018
Orphan designation: R)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride, for the: Treatment of hereditary angioedema
Europe - EMA - European Medicines Agency
3-8-2018
Human medicines European public assessment report (EPAR): Jentadueto, linagliptin / metformin hydrochloride, Revision: 14, Authorised
Europe - EMA - European Medicines Agency
3-8-2018
Human medicines European public assessment report (EPAR): Ameluz, 5-aminolevulinic acid hydrochloride, Revision: 12, Authorised
Europe - EMA - European Medicines Agency
3-8-2018
Human medicines European public assessment report (EPAR): Ristfor, sitagliptin / metformin hydrochloride, Revision: 18, Authorised
Europe - EMA - European Medicines Agency
1-8-2018
Human medicines European public assessment report (EPAR): Ceplene, histamine dihydrochloride, Revision: 12, Authorised
Europe - EMA - European Medicines Agency
24-7-2018
Opinion/decision on a Paediatric investigation plan (PIP): Palexia and associated names; Yantil and associated names; Tapentadol and associated names, Tapentadol (hydrochloride), Therapeutic area: Pain
Europe - EFSA - European Food Safety Authority EFSA Journal
24-7-2018
Orphan designation: Ambroxol hydrochloride, for the: Treatment of amyotrophic lateral sclerosis
Europe - EMA - European Medicines Agency
5-7-2018
Opinion/decision on a Paediatric investigation plan (PIP): Striverdi, Respimat, Olodaterol (hydrochloride), Therapeutic area: Pneumology-allergology
Europe - EFSA - European Food Safety Authority EFSA Journal
20-2-2019
Glibenclamide / metformin hydrochloride: List of nationally authorised medicinal products - PSUSA/00002002/201806
Glibenclamide / metformin hydrochloride: List of nationally authorised medicinal products - PSUSA/00002002/201806
Europe - EMA - European Medicines Agency
20-2-2019
Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/2018
Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/2018
Europe - EMA - European Medicines Agency
20-2-2019
Orphan designation: Histamine dihydrochloride, Treatment of acute myeloid leukaemia, 11/04/2005, Expired
Orphan designation: Histamine dihydrochloride, Treatment of acute myeloid leukaemia, 11/04/2005, Expired
Europe - EMA - European Medicines Agency
20-2-2019
Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0354/2018
Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0354/2018
Europe - EMA - European Medicines Agency
19-2-2019
Orphan designation: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride, Treatment of Kabuki syndrome, 19/11/2018, Positive
Orphan designation: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride, Treatment of Kabuki syndrome, 19/11/2018, Positive
Europe - EMA - European Medicines Agency
19-2-2019
Opinion/decision on a Paediatric investigation plan (PIP): Phenylephrine hydrochloride,ketorolac trometamol (OMS302), decision type: , therapeutic area: , PIP number: P/0362/2018
Opinion/decision on a Paediatric investigation plan (PIP): Phenylephrine hydrochloride,ketorolac trometamol (OMS302), decision type: , therapeutic area: , PIP number: P/0362/2018
Europe - EMA - European Medicines Agency
5-2-2019
Opinion/decision on a Paediatric investigation plan (PIP): Landiolol (hydrochloride), decision type: , therapeutic area: , PIP number: P/0273/2018
Opinion/decision on a Paediatric investigation plan (PIP): Landiolol (hydrochloride), decision type: , therapeutic area: , PIP number: P/0273/2018
Europe - EMA - European Medicines Agency
5-2-2019
Opinion/decision on a Paediatric investigation plan (PIP): Eviplera,emtricitabine,Rilpivirine (hydrochloride),Tenofovir (disoproxil fumarate), decision type: , therapeutic area: , PIP number: P/0274/2018
Opinion/decision on a Paediatric investigation plan (PIP): Eviplera,emtricitabine,Rilpivirine (hydrochloride),Tenofovir (disoproxil fumarate), decision type: , therapeutic area: , PIP number: P/0274/2018
Europe - EMA - European Medicines Agency
4-2-2019
Opinion/decision on a Paediatric investigation plan (PIP): Edurant,Rilpivirine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0322/2018
Opinion/decision on a Paediatric investigation plan (PIP): Edurant,Rilpivirine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0322/2018
Europe - EMA - European Medicines Agency
1-2-2019
Summary of opinion: Doxolipad,doxorubicin hydrochloride, 31/01/2019, Negative
Summary of opinion: Doxolipad,doxorubicin hydrochloride, 31/01/2019, Negative
Europe - EMA - European Medicines Agency
31-1-2019
Opinion/decision on a Paediatric investigation plan (PIP): Ciprofloxacin (hydrochloride), decision type: , therapeutic area: , PIP number: P/0253/2018
Opinion/decision on a Paediatric investigation plan (PIP): Ciprofloxacin (hydrochloride), decision type: , therapeutic area: , PIP number: P/0253/2018
Europe - EMA - European Medicines Agency
31-1-2019
Opinion/decision on a Paediatric investigation plan (PIP): Cariprazine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0301/2018
Opinion/decision on a Paediatric investigation plan (PIP): Cariprazine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0301/2018
Europe - EMA - European Medicines Agency
29-1-2019
Chlorphenoxamine hydrochloride : List of nationally authorised medicinal products - PSUSA/00010361/201805
Chlorphenoxamine hydrochloride : List of nationally authorised medicinal products - PSUSA/00010361/201805
Europe - EMA - European Medicines Agency
28-1-2019
Opinion/decision on a Paediatric investigation plan (PIP): Sarizotan (hydrochloride), decision type: , therapeutic area: , PIP number: P/0287/2018
Opinion/decision on a Paediatric investigation plan (PIP): Sarizotan (hydrochloride), decision type: , therapeutic area: , PIP number: P/0287/2018
Europe - EMA - European Medicines Agency
28-1-2019
Clomicalm (Elanco GmbH)
Clomicalm (Active substance: Clomipramine hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)720 of Mon, 28 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/000039/T/0030
Europe -DG Health and Food Safety
23-1-2019
Orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride-, Treatment of diffuse large B-cell lymphoma, 27/06/2016, Positive
Orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride-, Treatment of diffuse large B-cell lymphoma, 27/06/2016, Positive
Europe - EMA - European Medicines Agency
22-1-2019
Orphan designation: Doxorubicin hydrochloride (in heat-sensitive liposomes), Treatment of hepatocellular carcinoma, 23/02/2011, Positive
Orphan designation: Doxorubicin hydrochloride (in heat-sensitive liposomes), Treatment of hepatocellular carcinoma, 23/02/2011, Positive
Europe - EMA - European Medicines Agency
16-1-2019
EU/3/18/2125 (Isabelle Ramirez)
EU/3/18/2125 (Active substance: Benserazide hydrochloride) - Orphan designation - Commission Decision (2019)221 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000001719
Europe -DG Health and Food Safety
16-1-2019
EU/3/10/833 (FGK Representative Service GmbH)
EU/3/10/833 (Active substance: Doxorubicin hydrochloride (in heat-sensitive liposomes)) - Transfer of orphan designation - Commission Decision (2019)237 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003113
Europe -DG Health and Food Safety
16-1-2019
EU/3/16/1672 (Celgene Europe B.V.)
EU/3/16/1672 (Active substance: 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride) - Transfer of orphan designation - Commission Decision (2019)236 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003283
Europe -DG Health and Food Safety
11-1-2019
Opinion/decision on a Paediatric investigation plan (PIP): Octenidine (dihydrochloride), decision type: , therapeutic area: , PIP number: P/0240/2018
Opinion/decision on a Paediatric investigation plan (PIP): Octenidine (dihydrochloride), decision type: , therapeutic area: , PIP number: P/0240/2018
Europe - EMA - European Medicines Agency
13-12-2018
Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)
Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)
Europe - EMA - European Medicines Agency
13-12-2018
Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance
Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance
Europe - EMA - European Medicines Agency
11-12-2018
Epinephrine mepivacaine hydrochloride, mepivacaine norepinephrine, mepivacaine: List of nationally authorised medicinal products - PSUSA/00001979/201803
Epinephrine mepivacaine hydrochloride, mepivacaine norepinephrine, mepivacaine: List of nationally authorised medicinal products - PSUSA/00001979/201803
Europe - EMA - European Medicines Agency
28-11-2018
Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0177/2018
Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0177/2018
Europe - EMA - European Medicines Agency
28-11-2018
Opinion/decision on a Paediatric investigation plan (PIP): Mexiletine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0210/2018
Opinion/decision on a Paediatric investigation plan (PIP): Mexiletine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0210/2018
Europe - EMA - European Medicines Agency
28-11-2018
Econor (Elanco GmbH)
Econor (Active substance: Valnemulin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8038 of Wed, 28 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/42/T/54
Europe -DG Health and Food Safety
28-11-2018
Opinion/decision on a Paediatric investigation plan (PIP): ( 2R)-2-Amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-gu
Opinion/decision on a Paediatric investigation plan (PIP): ( 2R)-2-Amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-guanidino-1-hexanone hexahydrochloride, decision type: , therapeutic area: , PIP number: P/0134/2018
Europe - EMA - European Medicines Agency
28-11-2018
Opinion/decision on a Paediatric investigation plan (PIP): naloxone (hydrochloride), decision type: , therapeutic area: , PIP number: P/0146/2018
Opinion/decision on a Paediatric investigation plan (PIP): naloxone (hydrochloride), decision type: , therapeutic area: , PIP number: P/0146/2018
Europe - EMA - European Medicines Agency
27-11-2018
Opinion/decision on a Paediatric investigation plan (PIP): (R)-2-amino-3-phenylpropylcarbamate hydrochloride (solriamfetol), decision type: , therapeutic area: , PIP number: P/0207/2018
Opinion/decision on a Paediatric investigation plan (PIP): (R)-2-amino-3-phenylpropylcarbamate hydrochloride (solriamfetol), decision type: , therapeutic area: , PIP number: P/0207/2018
Europe - EMA - European Medicines Agency
26-11-2018
Wakix (Bioprojet Pharma)
Wakix (Active substance: Pitolisant hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7974 of Mon, 26 Nov 2018
Europe -DG Health and Food Safety
21-11-2018
EU/3/18/2082 (Takeda Pharma A/S)
EU/3/18/2082 (Active substance: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride) - Orphan designation - Commission Decision (2018)7791 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/040/18
Europe -DG Health and Food Safety
13-11-2018
EU/3/17/1836 (Zogenix GmbH)
EU/3/17/1836 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7576 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/233/16/T/01
Europe -DG Health and Food Safety
13-11-2018
EU/3/13/1219 (Zogenix GmbH)
EU/3/13/1219 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7575 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/140/13/T/01
Europe -DG Health and Food Safety
1-11-2018
Dexdomitor (Orion Corporation)
Dexdomitor (Active substance: dexmedetomidine hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7380 of Thu, 01 Nov 2018
Europe -DG Health and Food Safety
31-10-2018
Evista (Daiichi Sankyo Europe GmbH)
Evista (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7342 of Wed, 31 Oct 2018
Europe -DG Health and Food Safety
26-9-2018
Sileo (Orion Corporation)
Sileo (Active substance: Dexmedetomidine hydrochloride) - Centralised - Yearly update - Commission Decision (2018)6325 of Wed, 26 Sep 2018
Europe -DG Health and Food Safety
18-9-2018
Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/201801
Europe - EMA - European Medicines Agency
10-9-2018
Phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010430/201711
Europe - EMA - European Medicines Agency
10-9-2018
Ciprofloxacin hydrochloride / hydrocortisone: List of nationally authorised medicinal products - PSUSA/00000774/201711
Europe - EMA - European Medicines Agency
10-8-2018
Brinavess (Correvio)
Brinavess (Active substance: vernakalant hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5523 of Fri, 10 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1215/T/31
Europe -DG Health and Food Safety
30-7-2018
Segluromet (Merck Sharp and Dohme B.V.)
Segluromet (Active substance: ertugliflozin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5103 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4314/T/2
Europe -DG Health and Food Safety
30-7-2018
Ceplene (Noventia Pharma Srl)
Ceplene (Active substance: Histamine dihydrochloride) - Centralised - Renewal - Commission Decision (2018)5116 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/796/R/36
Europe -DG Health and Food Safety
23-7-2018
Optruma (Eli Lilly Nederland B.V.)
Optruma (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4893 of Mon, 23 Jul 2018
Europe -DG Health and Food Safety
12-7-2018
Econor (Elanco Europe Ltd)
Econor (Active substance: Valnemulin hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4580 of Thu, 12 Jul 2018
Europe -DG Health and Food Safety
11-7-2018
Ariclaim (Eli Lilly Nederland B.V.)
Ariclaim (Active substance: duloxetine hydrochloride) - Centralised - Withdrawal - Commission Decision (2018)4515 of Wed, 11 Jul 2018
Europe -DG Health and Food Safety
5-7-2018
Scientific guideline: Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open
This document provides product-specific guidance on the demonstration of the bioequivalence of pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml.
Europe - EMA - European Medicines Agency
3-7-2018
Efficib (Merck Sharp and Dohme B.V.)
Efficib (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4254 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/896/T/90
Europe -DG Health and Food Safety
3-7-2018
Ristfor (Merck Sharp and Dohme B.V.)
Ristfor (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4249 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1235/T/77
Europe -DG Health and Food Safety
3-7-2018
Velmetia (Merck Sharp and Dohme B.V.)
Velmetia (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4252 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/862/T/93
Europe -DG Health and Food Safety
3-7-2018
Janumet (Merck Sharp and Dohme B.V.)
Janumet (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4251 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/861/T/90
Europe -DG Health and Food Safety